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Head and neck squamous cell carcinomas are among the most common neoplasms worldwide and characterized by local tumor
aggressiveness,highrateofearlyrecurrences,development ofmetastasis,andsecondprimarycancers.Despitemoderntherapeutic
strategies and sophisticated surgical management, overall survival-rates remained largely unchanged over the last decades. Thus,
the need for novel treatment options for this tumor entity is undeniable. A key event in carcinogenesis is the uncontrolled
modulation of genetic programs. Nuclear receptors belong to a large superfamily of transcription factors implicated in a broad
spectrum of physiological and pathophysiological processes, including cancer. Several nuclear receptors have also been associated
withheadandneckcancer.Thisreviewwillsummarizetheirmodeofaction,prognostic/therapeuticrelevance,aswellaspreclinical
and clinical studies currently targeting nuclear receptors in this tumor entity.
Copyright © 2009 Shirley K. Knauer. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Most malignancies of the upper aerodigestive tract
(Figure 1), comprising the naso-, oro-, hypo-, and
laryngopharynx, are squamous cell carcinomas. Head
and neck squamous cell carcinomas (HNSCCs) are the
primary tumor type in head and neck cancer (HNC),
characterized by local tumor aggressiveness, high rate of
early recurrences, metastasis, and development of second
primary tumors, which are the major cause of morbidity
and mortality in HNSCC (details in [1–4]). More than
90% of HNC cases are induced by chronic exposure to
carcinogens enclosed in all forms of tobacco, synergized
by heavy alcohol consumptions and poor diet (see [5, 6]).
It is estimated that about 5%–10% of suspicious lesions
arising in the mucous membranes of the mouth, pharynx,
and larynx undergo malignant transformation. Cure rates of
early disease (stage I and II) range between 70% and 80%,
and chemoprevention strategies seem promising to control
potentially malignant oral lesions (reviewed in [1–3]).
However, long-term survival rates, especially for advanced
HNC, have not improved signiﬁcantly over the last decades.
Despite modern therapeutic strategies and sophisticated
surgical management of the tumor, the estimated ﬁve-year
survival rate for advanced disease (30%–40%) remains
poor ([1–3] and references therein). Currently, rational
therapeutic strategies targeting growth factor receptors
by speciﬁc antibodies or kinase inhibitors have gained
increasing clinical relevance in particular for the treatment
of locally advanced cancer with the intent of preserving
speech and swallowing (see [1–3]). Thus, developing new
therapeutic strategies and deﬁning novel target proteins for
the treatment of advanced HNC is of particular importance.
In this respect, nuclear receptors (NRs) are transcription
factors implicated in cancer development and are recently
attracting major interest as therapeutic targets (see [7, 8]).
As NRs modulate cell proliferation, apoptosis, invasion, and
migration, clearly representing hallmarks of cancer cells,
several highly successful cancer drugs target this receptor
family [8–11]. Since several NRs have been shown to be
expressed also in head and neck cancer cells, NRs are
most likely also contributing to HNSCC development and
progression [12, 13].
NRsbelongtoalargesuperfamilyoftranscriptionfactors
and based on sequence comparison are currently classiﬁed
into seven subfamilies (Table 1). These transcription factors2 Journal of Oncology
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Figure 1: Schematic anatomy of the head and neck region. Head
and neck cancer includes diﬀerent types of malignancies that can
develop in the mouth, nose and throat.
are able to modulate transcription of a variety of target genes
by several distinct mechanisms, including both transcrip-
tionalactivationandrepression[7,8,14,15].Transcriptional
regulation can either be ligand-dependent or -independent,
genomic or nongenomic, allowing NRs to mediate gene
repression or its release, gene activation, or gene trans-
repression(detailsin[7,8,16]).Inparticular,thelargegroup
of so-called orphan nuclear receptors, for which natural
ligands are still unknown, do not exist at all (true orphans),
or have only recently been identiﬁed (adopted orphans) is
adding additional complexity to the ﬁeld (Table 1)( [ 8, 17],
and references within).
In contrast to cell surface growth factor receptors, such as
the epidermal growth factor receptor (EGFR), which activate
genetic programs through complex intracellular signaling
cascades, NRs are able to directly bind to speciﬁc DNA-
sequences, so-called hormone response elements (HREs).
Thus, NRs are composed of an N-terminal regulatory
domain (activation function 1 = AF1), followed by a DNA-
binding domain (DBD), a ligand-binding domain (LBD),
and another C-terminal regulatory domain (activation func-
tion 2 = AF2) (Figure 2)[ 7, 8]. Despite their conserved
structural organization, the biological functions of NRs are
highly diverse. Nevertheless, two major modes of NR action
can be assigned, depending on their intracellular steady-state
localization in the absence of ligands (Figure 3). One group
of NRs is conﬁned to the cytoplasm within multiprotein-
complexes in the absence of ligand. Upon ligand binding,
theyactivelyenterthenucleusandbindtoHREsashomo-or
heterodimers (Figure 4, details in [7, 8]). Other NRs already
reside in the nucleus in a complex with corepressor pro-
teins, while ligand binding triggers corepressor dissociation
allowing the recruitment of coactivators [18, 19]. However,
in order to fulﬁll multiple biological tasks minor to major
deviations from these two modes of NR action exist [7, 8].
NRs are not only implicated in a broad spectrum of
physiological processes but are associated with many human
diseases including metabolic and cardiovascular disorders
as well as cancer. Beside their proven clinical relevance
for hormone regulated malignancies, there is rather limited
information on their pathophysiological role as well as
their prognostic and therapeutic potential for head and
neck cancer [7, 8, 12, 20–22]. Most studies were investi-
gating members of two classes of the NR superfamily, the
thyroid hormone receptor-like and the estrogen receptor-
like receptors (Table 1) .T h u s ,w ew i l lf o c u so nr e l e v a n t
members of these subfamilies, summarize their potential
diagnostic/prognostic value, and discuss their therapeutic
potential.
2. Thyroid Hormone Receptor-Like Receptors
2.1. Peroxisome Proliferator-Activated Receptors. Within the
thyroid hormone receptor-like receptor subfamily, the per-
oxisome proliferator-activated receptors (PPARs) show the
highestdiseaserelevanceforHNSCC.Todate,threeisoforms
of the PPAR (α,β/δ,a n dγ) have been identiﬁed, all able
to form heterodimers with retinoid X receptors (RXRs)
(see [23, 24]). PPARs are expressed in diﬀerent cell types
and activate the transcription of several genes involved in a
variety of biological processes, including lipid metabolism
and insulin sensitivity (see [23, 24]). Furthermore, a role
in limiting inﬂammation has also been reported [24, 25].
As tumor cell metabolism and inﬂammation appear to be
critical for tumorigenesis and clinical outcome, NRs may
thus directly or/and indirectly modulate malignancies [26,
27]. As such, PPARγ is overexpressed in many epithelial
malignancies [22, 28, 29] including oral squamous cell
carcinoma [30].
Intheabsenceofligand,PPARsarecomplexedwithcore-
pressor proteins, thus acting as transcriptional repressors.
Ligand binding induces conformational changes facilitating
heterodimerization with RXR, thus leading to the attraction
of transcriptional coactivators (Figures 3 and 4)( s e e[ 19,
24]). Natural and synthetic ligands for PPARs include
lipophilic molecules such as fatty acids and eicosanoids as
well as thiazolidinedione (TZD) drugs and derivates thereof
(overview in [7, 24, 31]). PPARγ ligands seem to exert
their eﬀects in a dosage-dependent manner [32], although
the detailed mechanism is currently not yet resolved.
The postulated cancer modulating mechanisms are diverse,
including eﬀects on Wnt signaling, inhibition of NFκB, as
well as the modulation of cell cycle regulators and pro- and
antiapoptotic proteins, which have been linked with head
and neck cancer (see [4, 23]).
Clinical Aspects of Peroxisome Proliferator-Activated Receptors
in HNSCC. In HNSCC, overexpression on the protein
level has been convincingly demonstrated for PPARβ and
PPARγ [12, 30, 33]. Agonist binding to PPARβ can induce
cell diﬀerentiation, growth arrest, and apoptosis of cancer
cells [34]. Additionally, such activating PPARβ ligands were
shown to exert antiproliferative on human colon and breast
cancers (details in [23, 24]) and were also suggested as
potential chemopreventive agents for oral carcinogenesis
[12, 35, 36]. Of note, since at least 1.6 million patientsJournal of Oncology 3
Table 1: Current classiﬁcation of the NR superfamily into subfamilies according to sequence homology. Trivial abbreviations are given in
brackets. NRs implicated in head and neck tumorigenesis are given in bold; asterisks indicate orphan receptors.
Subfamily Full name Subfamily members (trivial abbreviation)
Subfamily 1 Thyroid hormone receptor-like receptors
Subgroups
Peroxisomeproliferator-activated
receptors
Peroxisomeproliferator-activatedreceptor
(PPAR)α,β/δ,γ
Retinoicacid receptors Retinoicacid receptor (RAR)α,β,γ
Retinoic acid receptor-related orphan
receptors
Retinoic acid receptor-related orphan receptor
(ROR) α,β,γ
Rev-ErbA∗ Rev-ErbA (EAR1) α,β
Thyroid hormone receptors Thyroid hormone receptor (TR) α,β
Liver X receptor-like receptors∗ Liver X receptor (LXR) α,β; Farnesoid X
receptor (FXR)
Vitamin D receptor-like receptors
Vitamin D receptor (VDR); Pregnane X
receptor (PXR); Constitutive androstane
receptor (CAR)
Subfamily 2 Retinoid X receptor-like receptors
Subgroups
Hepatocyte nuclear factor-4 Hepatocyte nuclear factor-4 (HNF-4) α,γ
Retinoid X receptors Retinoid X receptor (RXR) α,β,γ
Testicular receptors∗ Testicular receptor 2, 4 (TR2/4)
Tailless-like receptors∗
Human homologue of the Drosophila tailless
gene (TLX); Photoreceptor cell-speciﬁc nuclear
receptor (PNR)
Chicken ovalbumin upstream
promoter-transcription factor-like
receptors∗
Chicken ovalbumin upstream
promoter-transcription factor (COUP-TF) I,
II; V-erbA-related (EAR2)
Subfamily 3 Estrogen receptor-like receptors
Subgroups
Estrogenreceptors Estrogenreceptor (ER)α,β
Estrogen related receptors∗ Estrogen-related receptor (ERR) α,β,γ
3-Ketosteroid receptors
Androgenreceptor(AR);Progesterone
receptor (PR);Glucocorticoid receptor (GR);
Mineralocorticoid receptor (MR);
Subfamily 4 Nerve growth factor IB-like receptors
Nerve Growth factor IB/ Nuclear receptor
related/ Neuron-derived orphan
receptor∗
Nerve Growth factor IB (NGF-IB); Nuclear
receptor related 1 (NURR1); Neuron-derived
orphan receptor 1 (NOR1)
Subfamily 5 Steroidogenic factor-like receptors
Steroidogenic factor/Liver receptor
homolog∗
Steroidogenic factor 1 (SF1); Liver receptor
homologue-1 (LHR1)
Subfamily 6 Germ cell nuclear factor-like receptors
Germ cell nuclear factor∗ Germ cell nuclear factor (GCNF)
Subfamily 0 Miscellaneous receptors
Dosage-sensitive sex reversal, adrenal
hypoplasia critical region/Small
heterodimer partner∗
Dosage-sensitive sex reversal, adrenal
hypoplasia critical region, on chromosome X,
gene 1 (DAX); Small heterodimer
partner(SHP)
take antidiabetic drugs that function as PPARβ ligands,
epidemiological data on their long-term eﬀects on tumor
prevention would therefore be of value to rationally design
cancer chemoprevention trials.
Paradoxically, not only PPARγ agonists are considered as
potentialtherapeuticagentsincancertherapybutalsoantag-
onistswerestudiedinthisrespect[30].PPARγ inhibitionwas
shown to induce apoptosis and anoikis and inhibit tumor
cell invasion in squamous cell carcinomas [30]. Moreover,
the results of several studies indicated that the growth-
inhibiting activity of PPARγ ligands in OSCC may be PPARγ
independent [37]. Others showed that the observed eﬀects
were strongly dependent on PPARγ-expression [12, 38]a s
well as on the type and concentration of the agonist [39].4 Journal of Oncology
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Figure 2: Domain organization and structural binding modes of NRs. Upper panel: NRs are composed of an N-terminal regulatory domain
(activation function 1 = AF1), followed by a DNA-binding domain (DBD), a ligand-binding domain (LBD), and a C-terminal domain
(activation function 2 = AF2). Left panel: 3D model illustrating how the DBDs of the RAR/RXR heterodimer (PDB 1DSZ) interact with their
target DNA-sequence. Right panel: solid ribbon representation illustrating the LBD of the RAR/RXR heterodimer (PDB 1DKF) complexed
with the ligands 9-cis-RA for RXR (PDB 3LBD) and ATRA for RAR (PDB 2LBD). PDB ﬁles are taken from the RCBS Protein Data Bank
(http://www.pdb.org).
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Figure 3: Simpliﬁed model illustrating the two major modes of NR activation. Natural or synthetic ligands diﬀuse through the cell membrane
and bind to cytosolic or nuclear NRs. Ligand binding to cytoplasmic NRs triggers conformational changes resulting in dissociation of heat
shock proteins (HSPs) and receptor dimerization, allowing active nuclear import and transactivation by binding to HREs. Other NRs are
constitutively nuclear and complexed with corepressors in the absence of ligands. Ligand binding induces conformational changes resulting
in the recruitment of coactivators to activate transcription of target genes.Journal of Oncology 5
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Figure 4: DNA-binding modes of NRs implicated in HNSCC.
RAR can heterodimerize with PPARs, which can be activated by
lipophilic ligands. Alternatively, RARs are able to heterodimerize
with RXRs, which are activated by 9-cis RA. Such heterodimers
can bind to speciﬁc half-site retinoic acid (RARE) or peroxisome
proliferator response elements (PPREs) direct repeats in the DNA
oftargetgenes.Estradiolbindinginducesestrogenreceptorhomod-
imerization and binding to palindromic half-site estrogen response
element(ERE)invertedrepeats.N:Anynucleotideoccurringwithin
the speciﬁc response element.
In the majority of OSCC cases, PPARγ mRNA could
be detected by RT-PCR [37]. By immunohistochemical
analysis of primary tumors, PPARγ was often found in low-
grade tumors, especially in tumor endothelium [38], and
a favorable impact of PPARγ expression on relapse-free
survival of the patients could be demonstrated [40].
The beneﬁcial eﬀects of PPARγ ligands on malignancies
were tested in several clinical trials, but outcomes proved
to be highly diverse. Some trials revealed 40% partial
responserates,whereasotherscouldnotshowanysigniﬁcant
beneﬁcial eﬀect [41, 42].
Moreover, one may speculate that the tumor modulating
eﬀects of PPARγ ligands are mediated indirectly by aﬀecting
the tumor microenvironment, such as cancer-associated
ﬁbroblasts or tumor endothelial cells [43]. In fact, PPARγ
ligands have been shown to aﬀect endothelial cell prolifer-
ation and migration and hence to regulate angiogenesis [44].
Also hypoxia-induced angiogenesis appears to be aﬀected
by PPARγ ligands in cancer therapy, even if the precise
mechanisms still remain unclear [45]. As angiogenesis is a
crucialaspectfortumordevelopment,therapyresistanceand
metastasis and inhibition of angiogenesis may hence have
contributed to the clinical beneﬁt observed.
In sum, PPARγ ligands appear to be of clinical beneﬁt
for the treatment of head and neck cancer, in partic-
ular for OSCC. Nevertheless, a more detailed molecular
knowledge on PPARγ biology is clearly required. Increasing
knowledge about the mode of action, speciﬁcity, and dosage-
dependence of PPAR agonistic and antagonistic ligands will
hopefully allow a better modeling of PPAR receptor function
a n dt h u sl e a dt oam o r ee ﬀective design of combinatorial
application schemes for cancer treatment and cancer preven-
tion in the future.
2.2. Retinoid Acid Receptors. Another group of thyroid
hormone receptor-like receptors implicated in HNSCC is the
retinoid acid receptors (RARs). RARs are characterized by
their activation via vitamin A derivatives. Upon activation,
RARs are able to heterodimerize with retinoid X receptors
(RXR) and to bind to speciﬁc hormone response elements
(HREs), thereby modulating transcription of target genes
(Figures 3 and 4)[ 8, 26, 46]. To date, a variety of coactivator-
and corepressor-proteins have been identiﬁed, allowing
the ﬁne-tuning of target gene transcription, ranging from
repression to full activation [18]. However, the molecular
details are just beginning to be uncovered [8, 26, 46].
RAR activation often leads to diﬀerentiation [47], cell-cycle
arrest [48], or apoptosis [49], culminating in the inhibiting
of tumor growth. Hence, its ligand retinoid acid (RA) or
derivates thereof are currently tested as therapeutic agents
in several cancer types (Table 2)[ 50]. Paradoxically, in some
malignancies RA rather promotes cell survival, which may
be due to the ability of RA to also activate PPARs, and as
a consequence expression of prosurvival genes is induced
[46]. Schug et al. could also show that the channeling of RA
betweenthesetwonuclearreceptorheterodimersismediated
by the cytoplasmic RA transporters CRABP2 and FABP5
and thus is strongly depending on the FABP5/CRABP2
ratio [46]. Thus, the channeling of RA to diﬀerent receptor
heterodimers appears to be crucial for the regulation of cell-
proliferation, positively or negatively aﬀecting tumor growth
[46]. Interestingly, both proteins were found diﬀerentially
expressed in metastatic and HPV-associated HNSCC, but
their biological and clinical eﬀects remain to be investigated
[51, 52].
An additional way of biological regulation is epigenetic
modulation playing an important role in cancer develop-
ment (reviewed in [53]). Gene silencing caused by aberrant
hypermethylation of CpG islands has not only been detected
in promoter regions of several tumor suppressor genes [53],
but several studies show hypermethylation of the RARβ
promoter in colon, breast, and lung cancers [54, 55]. In head
and neck carcinogenesis, hypermethylation of the RARβ
promoter was found to be indeed associated with RARβ
downregulationandhenceappearstobebiologicallyrelevant
[56].
Clinical Aspects of Retinoid Acid Receptors in HNSCC. As
outlined above, a rationale for the use of retinoids in
chemoprevention and cancer therapy was provided experi-
mentally by diﬀerent cellular [57] and animal models [58].
Moreover, this strategy was supported by epidemiological
data as well as by clinical trial outcomes [26, 59–61].
Several clinical chemoprevention trials including patients
with increased risk for developing cancer have shown that
treatment with retinoids resulted in the suppression of6 Journal of Oncology
Table 2: Overview of current clinical trials in the ﬁeld of HNSCC targeting NRs. The NCI protocol ID is given in bold (for further details
see: http://www.cancer.gov/CLINICALTRIALS).
NR Clinical trial / identiﬁer Drug Tumor entity Phase
PPAR
Pioglitazone in Preventing Head and
Neck Cancer in Patients With Oral
Leukoplakia/NCT00099021
Pioglitazone
Head and Neck
Cancer
Precancerous
/Nonmalignant
Condition
Phase II
ongoing
Rosiglitazone in Preventing Oral Cancer
in Patients With Oral
Leukoplakia/NCT00369174
Rosiglitazone
Head and Neck
Cancer
Precancerous
/Nonmalignant
Condition
Phase II
completed
RAR
Chemoprevention Study of Oral Cavity
Squamous Cell
Carcinoma/NCT00201279
13-cis Retinoic
acid
Oral Cavity
Squamous Cell
Carcinoma
Phase III
completed
Isotretinoin Plus Interferon in Treating
Patients With Recurrent
Cancer/NCT00002506
Isotretinoin
(combinedwith
Interferon a)
Head and Neck
Cancer
Esophageal Cancer
Phase II
ongoing
Isotretinoin, Interferon Alpha, and
Vitamin E in Treating Patients With Stage
III or Stage IV Head and Neck
Cancer/NCT00054561
Isotretinoin
(combinedwith
Interferon a and
Vitamin E)
Head and Neck
Cancer
Phase III
completed
ER
Combination Chemotherapy and
Tamoxifen in Treating Patients With
Solid Tumors/NCT00002608
Tamoxifen
(combinedwith
Cisplatin and
Doxorubicin)
Head and Neck
Cancer
Phase II
completed
precancerous lesions (see [26, 60]). Also, certain retinoids
inhibited the development of second primary tumors in
patients who had been previously treated for an early-stage
cancer but remained at high risk to relapse ([26, 60]a n d
references within). However, other studies using isotretinoin
orotherretinoids(e.g.,retinylpalmitate)didnotobserveany
beneﬁt in second primary tumor development, recurrence,
ormortalityofHNSCCorlungcancer[26,62].Currenttrials
(Table 2) are therefore aiming to resolve these controversies
by recruiting appropriate study populations as well as by the
use of novel drugs and improved treatment protocols.
Reduced RARβ mRNA levels have been observed not
only in several malignant tumors ([26, 56] and references
therein) but also in premalignant oral lesions ([63]a n d
references within). Unfortunately, until recently no anti-
bodies convincingly detecting RARβ were available. Thus,
most of the studies demonstrating RARβ downregulation
were based on in situ hybridization and could therefore
only show a decrease in the amount of mRNA. Ralhan et
al. were the ﬁrst to demonstrate decreased expression of
the RXRα and RARα/β/γ on protein level correlating with
diﬀerent stages of OSCC development and progression [64].
The molecular mechanism leading to downregulation or loss
of RARβ is poorly understood, but it was suggested that
expression of RARβ could depend on the intracellular level
of retinoids [26]. Several studies demonstrated a decrease in
the amount of RARβ during vitamin A deﬁciency as well
as its upregulation by RA. Additionally, there is evidence
that retinoic acid induces the expression of RARβ mRNA
in certain cell lines, but not in the malignant counterparts
of these cells. Thus, transformed cells may have developed
an aberrant response to retinoic acid due to the deregulated
expression of coactivator/repressor proteins [26]. Ralhan et
al. found a signiﬁcant association between the increase in
RARβ mRNA levels and clinical responses of premalignant
oral lesions to isotretinoin [65, 66]. Hence, RARβ indeed
seems to contribute to the suppression of the premalignant
phenotype and malignancy and may be causally linked
to the clinical outcome in chemoprevention trials with
retinoids [26, 67]. If so, RARβ may indeed serve as a
useful diagnostic marker in retinoid trials (Table 2) for the
prevention of oral carcinogenesis [68]. RAR modulation by
its agonist ligand all-trans retinoic acid (ATRA) represents
a successful example of how targeting of an NR contributes
to an impressive clinical beneﬁt in liquid tumors ([26]a n d
referencestherein).Lessonslearnedfromthesestudiesclearly
show that the therapeutic beneﬁt could be further enhanced
by combining ATRA with chromatin modulating agents,
such as histone deacetylase inhibitors [69]. Nevertheless, the
design of receptor speciﬁc drugs as well as an in depth
understanding of the molecular regulation of RAR biology is
required in order to fully exploit its therapeutic beneﬁt and
minimize potential side-eﬀects in the area of head and neck
cancer [7, 26].
3. Estrogen Receptor-Like Receptors
This subfamily is composed of the estrogen receptors
(ERα and ERβ), the estrogen-related receptor, and the 3-
ketosteroid receptors [10].Journal of Oncology 7
Table 3: Nuclear receptor target genes playing pivotal roles in diverse biological processes and cellular homeostasis were described to be
diﬀerentially expressed in head and neck cancer.
NR Target gene Function Reference - target gene Reference - head and neck
PPAR G0S2 Cell cycle Zandbergen et al. Biochem J 2005 Tokumaru et al. Cancer Res 2004
PDK1 Energy
homeostasis Degenhardt et al. J Mol Biol 2007 Wigﬁeld et al. Br J Cancer 2008
RAR
p21WAF1/CIP1 Cell cycle Liu et al. J Biol Chem 1996 Kapranos et al. Anticancer Res 2001
BIRC5/surviving Apoptosis Pratt et al. JC e l lB i o c h e m2003 Engels et al. JP a t h o l2007
C/EBPε Transcription
factor Schwarz et al. M o lC e l lB i o l1997 Bennett et al. Cancer Res 2007
CRABP Carrier protein Nezzar et al. Mol Vis 2007 Won et al. Metabolism 2004
cyclins, CDK Cell cycle Bour et al. Trends Cell Biol 2007 Jeannon et al. Clin Otolaryngol
Allied Sci 1998
ER
c-Myc Transcription
factor Markaverich et al. Steroids 2006 Pries et al. Int J Mol Med 2008
Cyclins Cell cycle Eeckhoute et al. Genes Dev 2006
Nakashima et al. Eur Arch
Otorhinolaryngol 2005 Lotayef et al.
Br J Cancer 2000
CRABP Carrier protein Li et al. J Biol Chem 2003 Vo et al. Anticancer Res 1998
CXCl12/SDF-1 Chemokine/ligand Hall et al. Mol Endocrinol 2003 Rehman et al. J Biol Chem 2008
cathepsin D Protease Bretschneider et al. Mol Oncol 2008 Strojan et al. Anticancer Res 2000
Besides the estrogen receptors themselves, many of the
genes regulated by the ER/estrogen-axis are critical for
cell proliferation, inhibition of apoptosis, stimulation of
invasion and metastasis, as well as for the promotion of
angiogenesis (see [10, 11] and references within). Since these
processes clearly state hallmarks of cancer cells, it is well
accepted that ERs are implicated in various cancer types
[9, 21]. Sex hormone receptors are expressed not only in
sexual organs but, amongst others, also in the vascular
epithelium [70], the lung epithelium [71], and the larynx
[72]. The expression of sex hormone receptors could also
be demonstrated in HNSCC by several studies [12, 13].
Both ER isoforms as well as the progesterone receptor (PR)
were detectable in cancer cells of the oral cavity, the salivary
gland, and in laryngeal/hypopharyngeal cancers, whereas the
tumor stroma was mostly negative [12, 13]. Expression of
ERα inversely correlated with that of ERβ in esophageal
carcinoma, and a correlation of ERβ levels with tumor
dediﬀerentiation and staging was suggested [73, 74].
Clinical Aspects of Estrogen Receptors in HNSCC. Consid-
ering the impressive beneﬁt of endocrine therapy in breast
cancer, targeting sex steroid hormone receptor as a potential
therapeutic strategy is also discussed for HNSCC [12, 75].
Currently, two main strategies are pursued in endocrine
therapy of ER-positive tumors. One is based on steroidal
antiestrogens like tamoxifen, which bind to the ER, block its
function,andultimatelyinducereceptordegradation[8,11].
The other is based on aromatase inhibitors and luteinizing
hormone-releasinghormoneagonists,whichreducethelevel
of circulating estrogen, thereby inhibiting ER activation
by depriving the receptor of its ligand [11]. Tamoxifen
was already shown to inhibit proliferation and invasion of
HNSCC cell lines, resulting in apoptosis, which could be
further enhanced upon combination with cisplatin [76–
78]. Thus, a therapeutic role of antiestrogens or aromatase
inhibitors in the clinical management of HNSCC is currently
under investigation, and the results of just completed clinical
trials (Table 2)a r ee a g e r l ya w a i t e d .
However, the precise molecular roles and impact of
estrogen receptor-like receptors for the onset and/or pro-
gression of head and neck cancer remain to be clariﬁed.
This knowledge will be required, in order to rationally
decidewhethertofurtherinvestigatethepotentialofmodern
endocrine therapy also for this tumor entity.
4. Conclusion
NRs are associated with head and neck cancer and hence
seem to be at least partially amenable for prevention
and/or treatment strategies. So far, three NR groups have
mainly been linked with HNSCC, the retinoic acid and the
peroxisomeproliferator-activatedandtheestrogenreceptors.
Also, target genes activated by these NR subfamilies (Table 3)
have been implicated as key elements in the molecular
circuits involved in head and neck cancer development and
progression. Reports on other members of the NR super-
familiy are rather scarce for this tumor entity, suggesting
that they have not been investigated so far. Taking the
thyroid hormone receptor as an example, many studies on
its relevance for various malignancies have been conducted,
whereas its role in head and neck cancer, including even
thyroid carcinomas, has not been analyzed in detail [79].
Likewise, data on the cancer-related biological functions of
orphan NRs are still missing for this tumor entity [7, 8]. As
now cancer cell metabolism is beginning to be considered as
“cancer’s Achilles’ heel”, it may be conceivable to speculate
that molecules present in diet, tobacco, or beetle nut might8 Journal of Oncology
deregulate the cell’s metabolism by aﬀecting NRs and as
such contribute to head and neck carcinogenesis [27, 80]. Of
note, the development of novel NR ligands with improved
speciﬁcity and activity is currently intensively pursued in
the area of metabolic diseases (see [7, 8, 81]). Hence, an
interdisciplinary exploitation of the existing knowledge of
NR pharmacobiology may result in novel HNSCC treatment
approaches.
In sum, keeping in mind the enormous success of NR
targeting therapeutics in several malignancies, a systematic
investigation of NR biology as well as of its clinical relevance
is highly desirable also for head and neck cancer. Together
with the outcomes of current clinical trials (Table 2), such
improved knowledge will hopefully result in strategies with
improved beneﬁt for the patient.
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